ASCO Annual Meeting

Mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed or refractory multiple myeloma.

Relacorilant plus nab-paclitaxel displayed OS benefit irrespective of prior taxane exposure or taxane-free interval in platinum-resistant ovarian cancer.

Results from the phase 3 MajesTEC-9 trial show superior PFS, OS, and ORR outcomes with teclistamab monotherapy in pretreated relapsed/refractory myeloma.

The phase 3 WU-KONG28 data showed that first-line sunvozertinib improved PFS and ORR vs chemotherapy in EGFR exon 20–mutant NSCLC.

Extended follow-up data from NRG-GY018 show a sustained OS benefit with pembrolizumab plus chemotherapy regardless of MMR status or post-study ICI therapy.

Final analysis of DREAMM-9 shows promising efficacy data and an optimal dosing schedule for BVRd in transplant-ineligible newly diagnosed multiple myeloma.

Chiauranib plus weekly paclitaxel cut the risk of progression or death by 57% vs placebo plus paclitaxel in platinum-resistant or refractory ovarian cancer.

The combination cut the risk of progression or death by 65% in the first phase 3 trial of an ADC plus pembrolizumab in this setting.

Amivantamab plus lazertinib led to a median OS of 41.0 months in EGFR-mutated advanced NSCLC.

At the 2026 ASCO Annual Meeting, results from the 7-year update of the phase 3 CROWN study were presented.

Poll results reflected some of the most anticipated presentations and fields of interest in hematologic oncology at the 2026 ASCO Annual Meeting.

Poll results reflect some of the most anticipated presentations and fields of interest in gynecologic oncology at the 2026 ASCO Annual Meeting.

Ahead of the 2026 ASCO Annual Meeting, results from the phase 3 FIGHT-302 study have been announced.

Hematologic oncology experts preview the top ASCO 2026 abstracts to watch in myeloma, MPNs, large B-cell lymphoma, and more.

Discover which gynecologic cancer abstracts experts believe may affect evolving treatment paradigms and patient care discussions at ASCO 2026.

GU experts identified key abstracts of interest from the upcoming ASCO Annual Meeting via OncLive’s social media.

Polls highlighted key abstracts of interest from the upcoming ASCO Annual Meeting.

Ahead of the 2026 ASCO Annual Meeting, experts in GI malignancies share the most anticipated research being presented during the meeting.

We spoke with leading voices in GU oncology to see which presentations they are most looking forward to during the 2026 ASCO Annual Meeting.

Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media.

Readers share their opinions on some of the most talked-about breast cancer abstracts they’re looking forward to seeing at ASCO 2026.

Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Expert investigators in GI cancers share their perspectives on the most significant updates in the space shared during the 2025 ASCO Annual Meeting.

First-line enfortumab vedotin plus pembrolizumab continued to demonstrate efficacy across subgroups of locally advanced or metastatic urothelial carcinoma.

Elacestrant-based combinations were safe and displayed preliminary efficacy in ER-positive/HER2-negative advanced breast cancer.

UGN-102 showed strong responses in patients with recurrent, intermediate-risk, low-grade non–muscle-invasive bladder cancer, per the phase 3 ENVISION trial.